Free Trial

Quest Diagnostics (DGX) Stock Forecast & Price Target

$145.10
+0.99 (+0.69%)
(As of 09:33 AM ET)

Quest Diagnostics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$148.69
2.48% Upside
High Forecast$165.00
Average Forecast$148.69
Low Forecast$130.00
TypeCurrent Forecast
7/16/23 to 7/15/24
1 Month Ago
6/16/23 to 6/15/24
3 Months Ago
4/17/23 to 4/16/24
1 Year Ago
7/16/22 to 7/16/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$148.69$146.67$144.18$151.20
Forecasted Upside2.48% Upside9.15% Upside8.27% Upside6.70% Upside
Get Quest Diagnostics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

DGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Quest Diagnostics Stock vs. The Competition

TypeQuest DiagnosticsMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.71
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside3.18% Upside851.24% Upside9.19% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$145.00 ➝ $165.00+19.25%
7/5/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$145.00 ➝ $153.00+8.59%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$152.00 ➝ $155.00+11.64%
4/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00+6.82%
4/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$139.00 ➝ $146.00+5.96%
4/24/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$145.00 ➝ $150.00+9.99%
4/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$150.00 ➝ $155.00+13.35%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$135.00+6.23%
2/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$140.00 ➝ $155.00+22.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$140.00 ➝ $160.00+16.82%
11/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$130.00 ➝ $140.00+4.09%
10/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$136.00 ➝ $130.00+5.03%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$145.00+6.35%
2/3/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$135.00 ➝ $140.00-0.44%
1/25/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$143.00 ➝ $146.00+0.75%
10/21/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$129.00 ➝ $140.00+3.97%
10/20/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Brackmann
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:59 AM ET.

DGX Forecast - Frequently Asked Questions

What is Quest Diagnostics' forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Quest Diagnostics is $148.69, with a high forecast of $165.00 and a low forecast of $130.00.

Should I buy or sell Quest Diagnostics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.

Does Quest Diagnostics's stock price have much upside?

According to analysts, Quest Diagnostics's stock has a predicted upside of 10.19% based on their 12-month stock forecasts.

Has Quest Diagnostics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Quest Diagnostics's stock had 1 upgrade by analysts.

What analysts cover Quest Diagnostics?

Quest Diagnostics has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., Mizuho, Robert W. Baird, Truist Financial, and UBS Group in the past 90 days.

Do Wall Street analysts like Quest Diagnostics more than its competitors?

Analysts like Quest Diagnostics less than other "medical" companies. The consensus rating for Quest Diagnostics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DGX compares to other companies.


This page (NYSE:DGX) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners